Gyn Onc Landmark: GOG 157 (3 v 6C for Early Stage Epithelial Ovarian Cancer) скачать в хорошем качестве

Gyn Onc Landmark: GOG 157 (3 v 6C for Early Stage Epithelial Ovarian Cancer)

3 cycles vs 6 cycles of carbo/taxol for patients with early stage epithelial ovarian cancer. This paper came out in 2006: GOG 157: Phase III on 6C v 3C of adjuvant Carbo/Taxol for early stage EOC [2006] Inclusion: Stage IA Grade 3, Stage IB Grade 3, IC, Stage 2, clear cell Histo: serous, mucinous, endometrioid, mixed, undifferentiated, Brenner, clear cell, transition Exclusion: Borderline and low malignancy potential tumors. Staging: Total hyst, BSO, resection of all gross dz, aspiration of free peritoneal fluid, peritoneal washing, infracolic OMX, selective bL PL and pALND, peritoneal bx from 4 pelvic locations and bL paracolic area, right diaphragm cytology or bx. Arm1: 3C Taxol 175 3h + Carbo AUC 7.5 q3w Arm1 Staging: N=213. (155 staging requirement met / 58 not met or incomplete document) Arm1 Completion: 3C= 203. 2C= 5. 1C= 2. No study tx= 2 Arm1 Result: 149=NED, 22=alive w recc dz. 36 died w recc dz Arm2: 6C Taxol 175 3h + Carbo AUC 7.5 q3w Arm2 Staging: N=214. (146 staging requirement met / 68 not met or incomplete document) Arm2 Completion: 6C=177, 5C=6, 4C=12, 3C=9, 2C=6, 1C=2, No study tx=2 Arm2 Result: 162=NED, 11=alive w recc dz. 32 died w recc dz RESULTS: 6C did not reduce recurrence rate when compared to 3C, but additional cycles did not increase toxicity. 77% change of dz-free at 5y with 3C (80% if 6C). *cancer rate of those who were completely staged vs not: was roughly the same. Link to paper: https://pubmed.ncbi.nlm.nih.gov/16860...